Multiple myeloma: open trials in Sweden

22 open trials have a site in Sweden. Registry data; only the trial team decides who can take part.

NCT05201781
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Trial Treatment · Phase 4 · Janssen Research & Development, LLC
Region Skane Skanes Universitetssjukhus, Lund · Uppsala University Hospital, Uppsala
Registry updated 2026-11-03
NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Region Dalarna, Falun · Karolinska University Hospital, Huddinge · Region Skane Skanes Universitetssjukhus, Lund · Region Oerebro Laen, Orebro
Registry updated 2026-11-03
NCT07589634
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Falu Lasarett Medicinkliniken Falun, Falun · Sahlgrenska Universitetssjukhuset, Gothenburg · Skanes universitetssjukhus, Lund · Karolinska University Hospital Huddinge, Stockholm · Akademiska sjukhuset, Uppsala
Registry updated 2026-11-03
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Karolinska University Hospital, Huddinge · Region Skane Skanes Universitetssjukhus, Lund
Registry updated 2026-10-29
NCT06953960
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1/2 · AbbVie
Soedra Aelvsborg Hospital Vaestra Goetalandsregionen, Boras · Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Karolinska University Hospital, Huddinge
Registry updated 2026-10-27
NCT05669989
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Trial Treatment · Phase 2 · Sanofi
Luleå
Registry updated 2026-10-15
2025-524793-42-00
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Cilag International
Region Dalarna, Falun · Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Karolinska University Hospital, Huddinge · Region Skane Skanes Universitetssjukhus, Lund · Uppsala University Hospital, Uppsala
Registry updated 2026-09-11
2025-524014-29-00
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
Trial Treatment · Phase 3 · AstraZeneca AB
Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Karolinska University Hospital, Huddinge · Region Skane Skanes Universitetssjukhus, Lund
Registry updated 2026-09-08
NCT06285318
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Research · Janssen-Cilag Ltd.
Sahlgrenska University Hospital, Gothenburg · Lanssjukhuset Ryhov, Jönköping · Karolinska Universitetssjukhuset, Stockholms · Uddevalla Hospital, Uddevalla
Registry updated 2026-08-28
NCT05020236
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Trial Treatment · Phase 3 · Pfizer
Soedra Aelvsborg Hospital Vaestra Goetalandsregionen, Boras · Falu Lasarett, Falun · Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Region Oestergoetland, Linkoping · Sunderby Sjukhus, Luleå · Region Skane Skanes Universitetssjukhus, Lund · Region Oerebro Laen, Orebro
Registry updated 2026-08-24
NCT06152575
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Trial Treatment · Phase 3 · Pfizer
Region Dalarna, Falun · Karolinska University Hospital, Huddinge · Region Oerebro Laen, Orebro
Registry updated 2026-08-24
NCT05714839
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Trial Treatment · Phase 1/2 · GlaxoSmithKline
Karolinska University Hospital, Huddinge
Registry updated 2026-08-19
NCT07764978
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Trial Treatment · Phase 3 · AstraZeneca
Gothenburg · Huddinge · Lund
Registry updated 2026-08-14
NCT04077307
A Study in Leukemia Patients With Karonudib
Trial Treatment · Phase 1 · Thomas Helleday Foundation
Karolinska University Hospital, Huddinge · Örebro University Hospital, Örebro
Registry updated 2026-08-06
2025-525105-20-00
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1/2 · AbbVie Deutschland GmbH & Co. KG
Soedra Aelvsborg Hospital Vaestra Goetalandsregionen, Boras · Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Karolinska University Hospital, Huddinge
Registry updated 2026-07-15
NCT04068597
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Trial Treatment · Phase 1/2 · CellCentric Ltd.
Karolinska Comprehensive Cancer Center, Stockholm
Registry updated 2026-06-24
NCT06932562
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Region Skane Skanes Universitetssjukhus, Lund
Registry updated 2026-03-25
NCT05879757
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Research · Takeda
Lund University Hospital, Lund
Registry updated 2026-02-18
2025-524022-18-00
Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment
Trial Treatment · Phase 2 · Vaestra Goetalandsregionen
Soedra Aelvsborg Hospital Vaestra Goetalandsregionen, Boras · Region Dalarna, Falun · Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Region Halland, Halmstad · Region Skane Helsingborg Hospital, Helsingborg · Karolinska University Hospital, Huddinge · Region Joenkoepings Laen, Jonkoping · Region Oestergoetland, Linkoping · Region Skane Skanes Universitetssjukhus, Lund · Region Oerebro Laen, Orebro · NU Hospital Group-Vaestra Goetalandsregionen, Trollhattan · Region Vaesterbotten, Umea · Uppsala University Hospital, Uppsala · Region Halland, Varberg
Registry updated 2026-02-16
NCT06616389
Study of ODX (OsteoDex) in Multiple Myeloma
Trial Treatment · Phase 1/2 · DexTech Medical AB
Karolinska Universitetssjukhuset Huddinge Cancerstudieenheten M62, Stockholm · Uddevalla Sjukhus, Hematologens dagvård, Uddevalla
Registry updated 2025-08-19
NCT06245629
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Research · Uppsala University
Akademiska sjukhuset, Uppsala
Registry updated 2024-11-29
NCT04558931
Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
Trial Treatment · Phase 2 · Karolinska Institutet
Karolinska University Hospital Huddinge, Stockholm
Registry updated 2023-10-11

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error